{"brief_title": "Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy", "brief_summary": "This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.", "condition": ["Peripheral Nervous System Diseases", "Chemotherapy-Induced Peripheral Neuropathy"], "intervention_type": ["Drug"], "intervention_name": ["leteprinim potassium (Neotrofin)"], "criteria": "- Patient must have diagnosis of cancer and be receiving or have received chemotherapy that has resulted in sensory or motor neuropathy. - Sensory or motor neuropathy must be >/= grade 2 per Common Toxicity Criteria at baseline. - In patients diagnosed with multiple myeloma, grade 1 sensory or motor neuropathy is acceptable. - Patient must have normal hematological cell counts. - Patient must have a life expectancy of >/= 3 months.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "80 Years", "healthy_volunteers": "No", "mesh_term": ["Peripheral Nervous System Diseases", "Nervous System Diseases"], "id": "NCT00041795"}